Skip to content

A multi-center interventional study to assess pharmacokinetics, effectiveness and tolerability of prolonged-release Tacrolimus after Paediatric Kidney Transplantation (Pro-Tac)

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-516608-40-00
Acronym
Pro-Tac
Enrollment
30
Registered
2024-10-21
Start date
2022-02-23
Completion date
2026-01-08
Last updated
2026-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caucasian paediatric kidney transplant recipients

Brief summary

Full AUCs will be described by median, minimum and maximum, geometric mean, arithmetic mean, standard deviation and coefficient of variation and analysed using an ANOVA model on the log transformed AUC values comparing Envarsus® and Prograf® with sequence, subject within sequence and period as further fixed factors. The resulting 90% confidence interval must lie within the acceptance boundaries of 0.8 and 1.25.

Detailed description

The secondary pharmacokinetic and pharmacodynamic endpoints will be analysed analogous to the primary endpoint or assessed using descriptive statistics (such as absolute and relative frequencies, median and interquartile range, geometric mean, arithmetic mean and standard deviation, minimum and maximum and coefficients of variation) to compare both phases. The suitability of LSS for 24h-AUC calculation will be judged using Pearson’s correlation coefficients.

Interventions

Sponsors

Universitaetsklinikum Essen AöR
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Full AUCs will be described by median, minimum and maximum, geometric mean, arithmetic mean, standard deviation and coefficient of variation and analysed using an ANOVA model on the log transformed AUC values comparing Envarsus® and Prograf® with sequence, subject within sequence and period as further fixed factors. The resulting 90% confidence interval must lie within the acceptance boundaries of 0.8 and 1.25.

Secondary

MeasureTime frame
The secondary pharmacokinetic and pharmacodynamic endpoints will be analysed analogous to the primary endpoint or assessed using descriptive statistics (such as absolute and relative frequencies, median and interquartile range, geometric mean, arithmetic mean and standard deviation, minimum and maximum and coefficients of variation) to compare both phases. The suitability of LSS for 24h-AUC calculation will be judged using Pearson’s correlation coefficients.

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026